Research and Markets: Global Oral Oncolytics Series: Leukemia Outlook 2024

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/fhw8wx/oral_oncolytics) has announced the addition of the "Global Oral Oncolytics Series: Leukemia Outlook 2024" report to their offering.

The base year for the report is 2013. The report provides short-mid term and long term forecasts for the period 2014 - 2024. This forecast is supported by detailed research and analysis of drugs (both marketed / pipeline) which we believe will have a far-reaching impact on the market. Owing to the uncertainties associated with drug development and customer adoption trends, three different market scenarios are presented for each of the drugs studied in this exercise:

Chapter 2 provides an executive summary of the insights captured in the research. The summary offers a high level view on the likely evolution of oral targeted leukemia market.

Chapter 3 provides a general introduction to leukemia. Discussed, in detail, are the types of leukemia, common signs and symptoms, its occurrence / prevalence and the current treatment regimes.

Chapter 4 provides an overview of the global leukemia therapeutics market, specifically the targeted therapeutics which includes small molecule inhibitors and monoclonal antibodies. The market has been analyzed on the basis of the type of leukemia, drug classes, and leading drugs in each segment.

Chapter 5 analyzes the current and future state of the worldwide market of oral targeted leukemia drugs. This chapter includes detailed profiles of all the marketed drugs and the drugs in phase III clinical trials. Estimates of the overall market value of oral targeted leukemia drugs till 2024 are presented.

Chapter 6 offers a region wise market analysis of the oral targeted leukemia drugs. This chapter covers the geographical availability and reimbursement policies of the oral targeted leukemia drugs. The major regional markets considered are the US, Europe and Japan.

Chapter 7 provides analysis of the strengths, weaknesses, opportunities and threats impacting the oral targeted leukemia market, capturing key elements likely to influence future growth.

Chapter 8 summarizes the overall report. In this chapter, a recap of the key takeaways is provided as well as independent opinion based on the research and analysis described in earlier chapters.

Chapters 9 and 10 are appendices, which provide the list of companies and tabulated data for all the figures presented in the report.

For more information visit http://www.researchandmarkets.com/research/fhw8wx/oral_oncolytics

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals